Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma	Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, neoplasm	Active, not recruiting	Phase 2	2026-08-28		NCT04802590

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Institute of Cancer Research, United Kingdom	59
The Lymphoma Academic Research Organisation	20

45 results · Page 1 of 2

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
A.Z. Sint Jan AV	Bruges	Belgium	2
Centre Henri Becquerel	Rouen	France	59
Centre Hospitalier Lyon Sud	Pierre-Bénite	France	51
Centre Léon Bérard	Lyon	France	77
Ch Annecy Gennevois	Pringy	France	1
Ch D'Avignon - Hopital Henri Duffaut	Avignon	France	3
CH de Bretagne Atlantique - Hopital CHUBERT	Vannes	France	1
CH de Cornouaille	Quimper	France	3
CH de la Côte Basque	Bayonne	France	4
CH Henri Mondor	Créteil	France	1
CHD de Vendée	La Roche-sur-Yon	France	1
CHRU de Lille	Lille	France	13
CHU Bretonneau	Tours	France	10
CHU d'Angers	Angers	France	5
Chu de Bordeaux - Hopital Haut-Leveque - Centre Francois Magendie	Pessac	France	1
CHU de Brest - Hopital de la Cavale Blanche	Brest	France	2
CHU de DIJON	Dijon	France	12
CHU de Grenoble	La Tronche	France	7
CHU de Liege	Liège	Belgium	21
CHU de Montpellier	Montpellier	France	22
Chu de Nantes	Nantes	France	72
CHU de Reims	Reims	France	11
Chu Estaing	Clermont-Ferrand	France	14
CHU Jean Minioz	Besançon	France	1
CHU Nancy Brabois	Vandœuvre-lès-Nancy	France	1

Clinical trials